Longer-acting treatments for neovascular age-related macular degeneration—present and future

Matias Iglicki, David Pérez González, Anat Loewenstein, Dinah Zur

Research output: Contribution to journalReview articlepeer-review


The treatment of neovascular AMD (nAMD) has been revolutionized by the introduction of anti-vascular endothelial growth factor (VEGF) agents. Though, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings, where long-term outcomes are not as good as expected. This is due to undertreatment, i.e., fewer injection and low monitoring frequency. Treatment burden due to frequent injections remains a major limitation. Long-lasting treatments provide promising solutions for this unmet need by achieving better results with less mandatory injections. This review aims to cover the current state in this field and also discuss the mechanism of action, data from pivotal trials, and safety profile of long-acting treatments in present and future, going into details about the following agents: Brolucizumab, Faricimab, Abipicar, and Conbercept.

Original languageEnglish
Pages (from-to)1111-1116
Number of pages6
Issue number4
StatePublished - Apr 2021


Dive into the research topics of 'Longer-acting treatments for neovascular age-related macular degeneration—present and future'. Together they form a unique fingerprint.

Cite this